Literature DB >> 3377468

Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus.

J Portnoy1, R Hicks, F Pacheco, L Olson.   

Abstract

Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3377468      PMCID： PMC172227          DOI： 10.1128/AAC.32.4.589

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections.

Authors:  C B Hall; R G Douglas; R L Simons; J M Geiman
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

2.  From the National Institute of Allergy and Infectious Diseases. Update on clinical trials with exogenous interferon.

Authors:  J K Dunnick; G J Galasso
Journal:  J Infect Dis       Date:  1980-08       Impact factor: 5.226

3.  Interferon deficiency syndrome.

Authors:  S Levin; T Hahn
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

4.  Interferon in acute viral infections.

Authors:  S Levin
Journal:  Eur J Pediatr       Date:  1983-03       Impact factor: 3.183

5.  Antibodies to human leucocyte interferons in cancer patients.

Authors:  P W Trown; M J Kramer; R A Dennin; E V Connell; A V Palleroni; J Quesada; J U Gutterman
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

6.  Interferon in nasal secretions from infants with viral respiratory tract infections.

Authors:  K McIntosh
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

7.  Toxicity of interferon.

Authors:  G M Scott; D S Secher; D Flowers; J Bate; K Cantell; D A Tyrrell
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-25

8.  Respiratory syncytial virus in infants and children.

Authors:  R H Parrott; H W Kim; C D Brandt; R M Chanock
Journal:  Prev Med       Date:  1974-12       Impact factor: 4.018

9.  Evaluation of the human interferon system in viral disease.

Authors:  S Levin; T Hahn
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

10.  Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection.

Authors:  I Gresser; M G Tovey; M E Bandu; C Maury; D Brouty-Boyé
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307
View more
  7 in total

Review 1.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

2.  Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a.

Authors:  R Y Sung; J Yin; S J Oppenheimer; J S Tam; J Lau
Journal:  Arch Dis Child       Date:  1993-10       Impact factor: 3.791

3.  Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection.

Authors:  Stephania A Cormier; Bishwas Shrestha; Jordy Saravia; Greg I Lee; Li Shen; John P DeVincenzo; Young-In Kim; Dahui You
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4. 

Authors:  François Freymuth; Geneviève Eugène; Jacques Brouard; Astrid Vabret; Joëlle Petitjean; Françoise Bonnin
Journal:  Ann Inst Pasteur Actual       Date:  2000-04-05

Review 5.  Bronchiolitis. Origins and optimal management.

Authors:  M L Everard
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 6.  Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.

Authors:  Diego R Hijano; Luan D Vu; Lawrence M Kauvar; Ralph A Tripp; Fernando P Polack; Stephania A Cormier
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

Review 7.  Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections.

Authors:  Patricio L Acosta; Alana B Byrne; Diego R Hijano; Laura B Talarico
Journal:  J Immunol Res       Date:  2020-05-08       Impact factor: 4.818
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.